KLRC2 and glioblastoma: In particular, in glioblastoma the expression of both HLA-E and HLA-G might be exploited for an immunotherapy with adaptive NKG2C+ NK cells, which specifically recognize HLA-E molecules presenting a high affinity peptide derived from HLA-G.